Costa Daniel, Leiva Marta, Coyo Natàlia, Laguna Fernando, Ríos Jose, Peña Gimenez Maria Teresa
Departament de Medicina i Cirurgia Animal, Facultat de Veterinaria Edifici V, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain.
Fundació Hospital Clínic Veterinari, Campus Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain.
Vet Ophthalmol. 2016 Nov;19(6):449-453. doi: 10.1111/vop.12323. Epub 2015 Oct 17.
The objective of the study was to evaluate the effect of topical 1% cyclopentolate hydrochloride (CH) on tear production (TP), pupil size (PS), and intraocular pressure (IOP) in dogs.
Fifteen healthy beagle dogs from the UAB research-teaching colony.
Dogs without ocular diseases were included. Each animal received one drop of 1% CH ophthalmic solution in a randomly selected eye. TP, PS, and IOP were evaluated by means of STT-1, static pupillometry, and rebound tonometry, respectively. Evaluations were performed before drug instillation and at 0.5, 1, 2, 4, 8, 12, 24, 30, 36, 48, 54, 60, 72, 84, and 96 h postinstillation. Examinations took place in a room with fixed light intensity (40-55 lux). Statistical analysis was performed by means of generalized estimating equations for the effect on STT-1, pupil size, and IOP over time.
After unilateral application of 1% CH, significant pupillary dilation started at 30 min, reached its maximum at 12 h, and returned to pre-instillation size after 72 h. No significant effects were found on TP or IOP, at any time. No effects were observed in the untreated eye on any of the parameters evaluated.
Cyclopentolate hydrochloride could be considered a therapeutic alternative when use of a cycloplegic drug is needed and effects on tear production and IOP are unwanted.
本研究的目的是评估局部应用1%盐酸环喷托酯(CH)对犬泪液分泌(TP)、瞳孔大小(PS)和眼压(IOP)的影响。
来自UAB研究教学群体的15只健康比格犬。
纳入无眼部疾病的犬。每只动物在随机选择的一只眼中滴入一滴1% CH眼药水。分别通过Schirmer试验-1(STT-1)、静态瞳孔测量法和回弹眼压测量法评估TP、PS和IOP。在滴药前以及滴药后0.5、1、2、4、8、12、24、30、36、48、54、60、72、84和96小时进行评估。检查在光线强度固定(40 - 55勒克斯)的房间内进行。通过广义估计方程对STT-1、瞳孔大小和IOP随时间的影响进行统计分析。
单侧应用1% CH后,显著的瞳孔散大在30分钟时开始,12小时时达到最大,72小时后恢复到滴药前大小。在任何时间对TP或IOP均未发现显著影响。未处理的眼睛在评估的任何参数上均未观察到影响。
当需要使用睫状肌麻痹药物且不希望对泪液分泌和眼压产生影响时,盐酸环喷托酯可被视为一种治疗选择。